Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 3 of 3
Full-Text Articles in Medicine and Health Sciences
Circulating Tumor Dna To Monitor Treatment Response And Detect Acquired Resistance In Patients With Metastatic Melanoma, Elin S. Gray, Helen Rizos, Anna L. Reid, Suzanah Boyd, Michelle Pereira, Johnny Lo, Varsha Tembe, James Freeman, Jenny Lee, Richard Scolyer, Kelvin Siew, Chris Lomma, Adam Cooper, Muhammad Khattak, Tarek Meniawy, Georgina Long, Matteo Carlino, Michael Millward, Mel R. Ziman
Circulating Tumor Dna To Monitor Treatment Response And Detect Acquired Resistance In Patients With Metastatic Melanoma, Elin S. Gray, Helen Rizos, Anna L. Reid, Suzanah Boyd, Michelle Pereira, Johnny Lo, Varsha Tembe, James Freeman, Jenny Lee, Richard Scolyer, Kelvin Siew, Chris Lomma, Adam Cooper, Muhammad Khattak, Tarek Meniawy, Georgina Long, Matteo Carlino, Michael Millward, Mel R. Ziman
Research outputs 2014 to 2021
Repeat tumor biopsies to study genomic changes during therapy are difficult, invasive and data are confounded by tumoral heterogeneity. The analysis of circulating tumor DNA (ctDNA) can provide a non-invasive approach to assess prognosis and the genetic evolution of tumors in response to therapy. Mutation-specific droplet digital PCR was used to measure plasma concentrations of oncogenic BRAF and NRAS variants in 48 patients with advanced metastatic melanoma prior to treatment with targeted therapies (vemurafenib, dabrafenib or dabrafenib/trametinib combination) or immunotherapies (ipilimumab, nivolumab or pembrolizumab). Baseline ctDNA levels were evaluated relative to treatment response and progression-free survival (PFS). Tumor-associated ctDNA was …
Support After Brain Tumor Means Different Things: Family Caregivers' Experiences Of Support And Relationship Changes, T. Ownsworth, E. Goadby, Suzanne K. Chambers
Support After Brain Tumor Means Different Things: Family Caregivers' Experiences Of Support And Relationship Changes, T. Ownsworth, E. Goadby, Suzanne K. Chambers
Research outputs 2014 to 2021
Shorter hospital stays and greater emphasis on outpatient care means that family members have the primary responsibility for supporting a person with brain tumor to manage the physical, cognitive, behavioral, and emotional effects of the illness and its treatment. Given the integral role of family caregivers, it is essential to understand their experience of the impact of brain tumor and their own support needs. Accordingly, this qualitative study aimed to investigate family caregivers' experiences of support and relationship changes in the context of brain tumor. In-depth interviews were conducted with 11 family caregivers (8 spouse/partner, 3 parents) of people with …
Monitoring Changes In Circulating Tumour Cells As A Prognostic Indicator Of Overall Survival And Treatment Response In Patients With Metastatic Melanoma, Dragana Klinac, Elin S. Gray, James B. Freeman, Anna Reid, Samantha Bowyer, Michael Millward, Mel Ziman
Monitoring Changes In Circulating Tumour Cells As A Prognostic Indicator Of Overall Survival And Treatment Response In Patients With Metastatic Melanoma, Dragana Klinac, Elin S. Gray, James B. Freeman, Anna Reid, Samantha Bowyer, Michael Millward, Mel Ziman
Research outputs 2014 to 2021
Background: New effective treatments for metastatic melanoma greatly improve survival in a proportion of patients. However biomarkers to identify patients that are more likely to benefit from a particular treatment are needed. We previously reported on a multimarker approach for the detection of heterogenous melanoma circulating tumour cells (CTCs). Here we evaluated the prognostic value of this multimarker quantification of CTCs and investigated whether changes in CTC levels during therapy can be used as a biomarker of treatment response and survival outcomes.Methods: CTCs were captured by targeting the melanoma associated markers MCSP and MCAM as well as the melanoma stem …